Transcode Therapeutics, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2020 to 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Transcode Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2020 to 2024.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was -$5.92M, a 44.7% decline year-over-year.
  • Transcode Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was -$16.8M, a 9.66% increase year-over-year.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$16.8M, a 9.66% increase from 2023.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$18.5M, a 5.59% decline from 2022.
  • Transcode Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$17.6M, a 157% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$16.8M +$1.79M +9.66% Jan 1, 2024 Dec 31, 2024 10-K 2025-04-15
2023 -$18.5M -$981K -5.59% Jan 1, 2023 Dec 31, 2023 10-K 2025-04-15
2022 -$17.6M -$10.7M -157% Jan 1, 2022 Dec 31, 2022 10-K 2024-04-01
2021 -$6.84M -$4.5M -192% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-31
2020 -$2.34M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.